Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 8/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.74 |
| ▸ | CFTR | P13569 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.67 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.59 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23001307 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL29365020 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL22469941 | 1.00 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL27318281 | 0.92 | NLRP3 (0.86) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL25144914 | 0.90 | NLRP3 (1.00) | NLRP3PTPN1CFTRMEN1KMT2A | |
| SCHEMBL28687390 | 0.87 | NLRP3 (1.00) | NLRP3PTPN1MEN1KMT2ADUSP22 | |
| SCHEMBL28687393 | 0.87 | NLRP3 (1.00) | NLRP3PTPN1MEN1KMT2ADUSP22 | |
| SCHEMBL919042 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 | |
| SCHEMBL1881897 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 | |
| SCHEMBL1326698 | 0.81 | CFTR (1.00) | NLRP3CFTRMEN1KMT2ADUSP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12121565-B2 | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies | DUKE UNIVERSITY (US) | 2024-10-22 | — | — | US | disclosed |
| US-20220226480-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-07-21 | — | — | US | disclosed |
| EP-3941897-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | Integrated Nanotherapeutics Inc. (CA) | 2022-01-26 | — | — | EP | disclosed |
| US-20210077582-A1 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF ANTI-PD-1 ANTIBODY IMMUNOTHERAPY | DUKE UNIVERSITY (US) | 2021-03-18 | — | — | US | disclosed |
| WO-2020191477-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226480-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | LPXN, MLX, MGLL | NLRP3 341/4885PTPN1 2304/4885CFTR 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.